X
Xvivo perfusion
Organ preservation and perfusion technology for transplantation.
At a glance
- Founded
- 1998
- Headquarters
- Göteborgs Stad, Sweden
- Listing
- IPO 2012
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Xvivo perfusion.
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Patents
15 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Xvivo perfusion was the backer or acquirer, 2020–2022. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
3 deals across Xvivo perfusion's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Xvivo perfusion's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xvivo perfusion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xvivo perfusion on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.